Biokine Therapeutics Ltd.

Ness Ziona, Israel

Biokine Therapeutics Ltd.

Ness Ziona, Israel
SEARCH FILTERS
Time filter
Source Type

Patent
Biokine Therapeutics Ltd. | Date: 2015-12-09

Use of a polypeptide comprising a chemokine binding peptide as set forth in SEQ ID NO: 1 attached to an Fc domain or a fragment thereof is provided. The polypeptide is used in the manufacture of a medicament identified for the treatment of an ocular disease in a subject in need thereof.


Patent
Biokine Therapeutics Ltd. and BiolineRx | Date: 2014-10-30

There is provided a method of treating acute myeloid leukemia (AML). The method includes the step of administering to a patient having AML with a FMS-like tyrosine kinase 3 (FLT3)-mutation a therapeutically effective amount of a CXCR4-antagonistic peptide.


The present invention is directed to novel therapeutic uses of T-140 analog peptides and compositions comprising same. Specifically, the invention provides compositions and methods useful for providing improved bone marrow transplantation and in the treatment of other conditions wherein bone marrow depletion or suppression is involved.


The present invention is directed to novel therapeutic uses of T- 140 analog peptides and compositions comprising same. Specifically, the invention provides compositions and methods useful for providing improved bone marrow transplantation and in the treatment of other conditions wherein bone marrow depletion or suppression is involved.


Patent
Biokine Therapeutics Ltd. | Date: 2016-10-05

Novel polypeptides comprising a chemokine-binding peptide and an Fc fragment are disclosed. The polypeptides are capable of binding to certain chemokines so as to modulate their activity. These polypeptides can be used to modulate in vivo chemokine-dependent processes such as inflammation and autoimmunity, and to treat associated conditions.


Patent
Biokine Therapeutics Ltd. | Date: 2013-01-28

Novel peptidic or peptidomimetic agents or small molecules for modulating the biological effect of a chemokine. According to the present invention, the therapeutic agents preferably are endowed with the capacity to bind to certain chemokines in order to modulate the biological interaction between the target ligand, chemokine, and the respective target receptor, chemokine receptor. These peptides may be described as agonist ligands or antagonists. Next, preferably certain peptides share consensus sequences are described which characterize the families or categories of these modulator peptides.


Patent
Biokine Therapeutics Ltd. | Date: 2014-03-19

There is provided a method of treating a myeloid leukemia. The method includes the step of administering to a subject in need thereof a therapeutically effective amount of a CXCR4-antagonistic peptide and a therapeutically effective amount of a chemotherapeutic agent.


Patent
Biokine Therapeutics LTD. | Date: 2015-11-11

The present invention is directed to novel therapeutic uses of T-140 analog peptides and compositions comprising same. Specifically, the invention provides compositions and methods useful in cancer therapy.


Novel polypeptides comprising a chemokine-binding peptide and an Fc fragment are disclosed. The polypeptides are capable of binding to certain chemokines so as to modulate their activity. These polypeptides can be used to modulate in vivo chemokine-dependent processes such as inflammation and autoimmunity, and to treat associated conditions.


Patent
Biokine Therapeutics LTD. | Date: 2014-07-30

The present invention is directed to novel therapeutic uses of T-140 analog peptides and compositions comprising same. Specifically, the invention provides compositions and methods useful in cancer therapy.

Loading Biokine Therapeutics Ltd. collaborators
Loading Biokine Therapeutics Ltd. collaborators